Global Tech Reporter
SEE OTHER BRANDS

Get your daily news on science and technology

Global Tech Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Tech Reporter.

Press releases published on May 7, 2025

Magnite Reports First Quarter 2025 Results

Magnite Reports First Quarter 2025 Results

Contribution ex-TAC(1) Grows 12% Year-Over-Year Contribution ex-TAC(1) from CTV Grows 15% Year-Over-Year Adjusted EBITDA(1) Grows 47% Year-Over-Year NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Magnite (NASDAQ: MGNI), the largest independent sell-side …

electroCore Announces First Quarter 2025 Financial Results

electroCore Announces First Quarter 2025 Financial Results

First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call …

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio …

Fluence Energy, Inc. Reports Second Quarter 2025 Results; Lowers Full Year 2025 Guidance, Citing Decisions to Pause Certain U.S. Projects Due to Tariff Uncertainty

Fluence Energy, Inc. Reports Second Quarter 2025 Results; Lowers Full Year 2025 Guidance, Citing Decisions to Pause Certain U.S. Projects Due to Tariff Uncertainty

ARLINGTON, Va., May 07, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its …

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration …

New Toll Brothers Copperhaven Model Home Opens in West Jordan, Utah

New Toll Brothers Copperhaven Model Home Opens in West Jordan, Utah

WEST JORDAN, Utah, May 07, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL) the nation’s leading builder of luxury homes, today announced the grand opening of the new model home at its Copperhaven by Toll Brothers community located in the heart of …

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment …

FormFactor Announces Participation at Upcoming Conferences

FormFactor Announces Participation at Upcoming Conferences

LIVERMORE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) is pleased to announce its participation in the following investor conferences: B. Riley 25th Annual Investor Conference Location: The Ritz-Carlton, Marina del Rey Date:  …

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System

WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and …

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund …

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML …

Wireless Broadband Alliance Wi-Fi 7 Trials Demonstrate Significant Performance Gains for Real-World Enterprise Environments

Wireless Broadband Alliance Wi-Fi 7 Trials Demonstrate Significant Performance Gains for Real-World Enterprise Environments

Wi-Fi 7 delivers increased throughput, lower latency, and enhanced efficiency for high-demand applications, setting a new standard for enterprise connectivity LONDON, UNITED KINGDOM, May 7, 2025 /⁨EINPresswire.com⁩/ -- The Wireless Broadband Alliance (WBA …

Philomaxcap CEO and GenH2 Executive Chairman Josh McMorrow Joins Siemens Energy North America President Rich Voorberg

Philomaxcap CEO and GenH2 Executive Chairman Josh McMorrow Joins Siemens Energy North America President Rich Voorberg

Powerhouse Pair will Discuss “Impact of Hydrogen in the Energy Transition and its Role in Carbon Neutrality” at the Offshore Technology Conference (OTC) TITUSVILLE, FL, UNITED STATES, May 7, 2025 /⁨EINPresswire.com⁩/ -- GenH2 Corp. (a subsidiary of  …

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s …

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 …

Photronics Announces Upcoming Investor Events

Photronics Announces Upcoming Investor Events

BROOKFIELD, Conn., May 07, 2025 (GLOBE NEWSWIRE) -- Photronics, Inc. (Nasdaq:PLAB), a worldwide leader in photomask technologies and solutions, announced today its participation in the following upcoming financial conferences: Date: Thursday, May 29th …

Symbotic Reports Second Quarter Fiscal Year 2025 Results

Symbotic Reports Second Quarter Fiscal Year 2025 Results

WILMINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, announced financial results for its second quarter of fiscal year 2025, which ended on March 29, 2025. …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service